Jacobio Pharma Partners with AstraZeneca for KRAS Cancer Treatment Breakthrough
In a landmark development for cancer treatment, Jacobio Pharma has forged a global exclusive license agreement with AstraZeneca concerning the innovative Pan-KRAS inhibitor, JAB-23E73. This partnership signifies a pivotal moment for Jacobio, allowing for a broader reach in developing ground-breaking therapies for patients with KRAS-mutated cancers. As per the agreement, AstraZeneca is granted exclusive rights for the development and commercialization of JAB-23E73 outside of China. Meanwhile, both companies will collaborate on the drug's development and commercialization efforts within China, showcasing a concerted approach to tackling the pressing issue of cancer worldwide.
The financial structure of the agreement is robust, beginning with an upfront payment of $100 million to Jacobio. Additionally, the company stands to gain up to $1.915 billion in development and commercial milestone payments, along with tiered royalties on worldwide net sales. This partnership is anticipated to significantly bolster Jacobio's financial standing, facilitating accelerated efforts in global drug development and enhancing its presence within the oncology innovation landscape.
Yinxiang Wang, Ph.D., the Chairman and Co-CEO of Jacobio Pharma, expressed enthusiasm about the new collaboration, noting the potential impact on patient care. The joint effort aims to deliver cutting-edge treatments and improve patient outcomes for those suffering from KRAS-mutated cancers—conditions that typically present significant treatment challenges.
Matt Hellmann, Senior Vice President at AstraZeneca, highlighted the significance of KRAS as a critical oncogene in various cancers, including pancreatic, colorectal, and lung cancers. With JAB-23E73, AstraZeneca aims to progress new treatment regimens that could revolutionize standard care practices and improve survival rates for patients facing these dire health issues.
JAB-23E73, the result of Jacobio’s proprietary allosteric drug discovery platform, is a promising new treatment aimed at addressing a range of KRAS mutation subtypes. Research indicates that KRAS is one of the most frequently mutated oncogenes in cancer, being detected in about 23% of all cancer patients. Currently, JAB-23E73 is undergoing Phase I trials in both China and the United States, demonstrating early signs of anti-tumor efficacy.
This agreement not only strengthens Jacobio’s position in the oncology sector but also accelerates its ongoing research into the KRAS pathway. The company plans to continue delving into innovative therapeutics that involve KRAS inhibitors and their synergies with other treatment methodologies, including its Immuno-oncology programs and target-specific treatments designed for various KRAS mutation types.
Jacobio Pharma’s commitment to innovation is further underscored by its development centers located in key global markets, including Beijing, Shanghai, and Boston. Their research and development activities span a wide array of clinical trial sites worldwide, emphasizing a strategy focused on generating effective solutions for cancer treatment on a global scale. Through this partnership with AstraZeneca, Jacobio Pharma is poised to make significant strides forward in the fight against cancer, embodying a mission to elevate patient care and enhance survival rates through groundbreaking medical advancements.
The financial structure of the agreement is robust, beginning with an upfront payment of $100 million to Jacobio. Additionally, the company stands to gain up to $1.915 billion in development and commercial milestone payments, along with tiered royalties on worldwide net sales. This partnership is anticipated to significantly bolster Jacobio's financial standing, facilitating accelerated efforts in global drug development and enhancing its presence within the oncology innovation landscape.
Yinxiang Wang, Ph.D., the Chairman and Co-CEO of Jacobio Pharma, expressed enthusiasm about the new collaboration, noting the potential impact on patient care. The joint effort aims to deliver cutting-edge treatments and improve patient outcomes for those suffering from KRAS-mutated cancers—conditions that typically present significant treatment challenges.
Matt Hellmann, Senior Vice President at AstraZeneca, highlighted the significance of KRAS as a critical oncogene in various cancers, including pancreatic, colorectal, and lung cancers. With JAB-23E73, AstraZeneca aims to progress new treatment regimens that could revolutionize standard care practices and improve survival rates for patients facing these dire health issues.
JAB-23E73, the result of Jacobio’s proprietary allosteric drug discovery platform, is a promising new treatment aimed at addressing a range of KRAS mutation subtypes. Research indicates that KRAS is one of the most frequently mutated oncogenes in cancer, being detected in about 23% of all cancer patients. Currently, JAB-23E73 is undergoing Phase I trials in both China and the United States, demonstrating early signs of anti-tumor efficacy.
This agreement not only strengthens Jacobio’s position in the oncology sector but also accelerates its ongoing research into the KRAS pathway. The company plans to continue delving into innovative therapeutics that involve KRAS inhibitors and their synergies with other treatment methodologies, including its Immuno-oncology programs and target-specific treatments designed for various KRAS mutation types.
Jacobio Pharma’s commitment to innovation is further underscored by its development centers located in key global markets, including Beijing, Shanghai, and Boston. Their research and development activities span a wide array of clinical trial sites worldwide, emphasizing a strategy focused on generating effective solutions for cancer treatment on a global scale. Through this partnership with AstraZeneca, Jacobio Pharma is poised to make significant strides forward in the fight against cancer, embodying a mission to elevate patient care and enhance survival rates through groundbreaking medical advancements.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.